The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), in partnership with Allergy & Asthma Network (AAN), led a stakeholder consensus initiative to recommend outcomes that should be core across all phase 3 and 4 clinical drug trials for moderate to severe asthma.
| BALTIMORE, April 6, 2021 /PRNewswire/ -- The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), in partnership with Allergy & Asthma Network (AAN), led a stakeholder consensus initiative to recommend outcomes that should be core across all phase 3 and 4 clinical drug trials for moderate to severe asthma. The report, published in the Annals of Allergy, Asthma and Immunology, describes the multi-stakeholder consensus process used to prioritize nearly 100 outcomes down to a final set of five core outcomes. Participants represented many perspectives, including patients, clinicians, researchers, payers, health technology assessors, regulators, and drug development companies. “The coreASTHMA core outcome set is a triumph. Even in a condition like asthma, where the most important outcomes for clinical research might seem self-evident, valuable insights on outcome selection were gained through multistakeholder engagement. I am confident that as these insights are adopted into clinical research, producing more relevant data consistently, patients will be the ultimate winners,” says Donna Messner, President & CEO, CMTP. With many recently approved and additional emerging therapies in asthma, outcomes used in trials are heterogenous — creating challenges for drawing meaningful comparisons between these therapies. “Consistent inclusion of these outcomes will allow comparison across trials to provide further guidance on benefits of one therapeutic option versus another,” says Vickram Tejwani, Pulmonary and Critical Care Fellow, Johns Hopkins Hospital. Furthering their partnership, CMTP and AAN have also launched a follow-up initiative called coreASTHMA QoL to build upon the insight gained from coreASTHMA that current asthma-specific quality of life measures do not readily translate into meaningful improvements in patients’ lives. “The coreASTHMA project highlighted that asthma-specific quality of life is an important outcome to patients. In coreASTHMA QoL, we will ensure this outcome is measured in a way that is relevant to how patients perceive quality of life,” says Tonya Winders, President & CEO, AAN. About the Green Park Collaborative (GPC) About Allergy & Asthma Network (AAN) Contact Allergy & Asthma Network
SOURCE Center for Medical Technology Policy (CMTP) |
View original content to download multimedia:
